Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Argus Health
AstraZeneca
Queensland Health
Johnson and Johnson

Generated: April 22, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CLOMIPRAMINE HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Clomipramine Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00004310 Phase II Randomized Study of Intravenous Versus Oral Clomipramine in Patients With Obsessive Compulsive Disorder Unknown status Stanford University Phase 2 OBJECTIVES: I. Evaluate the efficacy of intravenous versus oral pulse loading of clomipramine (CMI) followed by a 12-week course of maintenance therapy in patients with obsessive compulsive disorder.
NCT00004310 Phase II Randomized Study of Intravenous Versus Oral Clomipramine in Patients With Obsessive Compulsive Disorder Unknown status National Center for Research Resources (NCRR) Phase 2 OBJECTIVES: I. Evaluate the efficacy of intravenous versus oral pulse loading of clomipramine (CMI) followed by a 12-week course of maintenance therapy in patients with obsessive compulsive disorder.
NCT00254735 Quetiapine Augmentation in Severe Obsessive Compulsive Disorder Completed AstraZeneca Phase 3 The purpose of the study is to evaluate the efficacy of quetiapine or placebo added to baseline treatment of SSRI/clomipramine for the treatment of OCD in adult subjects.
NCT00466609 Using Drug Augmentation to Treat Obsessive Compulsive Disorder Patients Who Did Not Respond to Previous Treatment Completed Conselho Nacional de Desenvolvimento Científico e Tecnológico Phase 4 This will be a controlled, randomized, double-blind and double-dummy study on the treatment augmentation strategy for obsessive compulsive disorder patients non-respondent to first line pharmacological treatment. The investigators will compare: fluoxetine maintenance at maximum dosage for additional 12 weeks; the association of fluoxetine with quetiapine; and the association of fluoxetine with clomipramine.
NCT00466609 Using Drug Augmentation to Treat Obsessive Compulsive Disorder Patients Who Did Not Respond to Previous Treatment Completed Fundação de Amparo à Pesquisa do Estado de São Paulo Phase 4 This will be a controlled, randomized, double-blind and double-dummy study on the treatment augmentation strategy for obsessive compulsive disorder patients non-respondent to first line pharmacological treatment. The investigators will compare: fluoxetine maintenance at maximum dosage for additional 12 weeks; the association of fluoxetine with quetiapine; and the association of fluoxetine with clomipramine.
NCT00466609 Using Drug Augmentation to Treat Obsessive Compulsive Disorder Patients Who Did Not Respond to Previous Treatment Completed Novartis Phase 4 This will be a controlled, randomized, double-blind and double-dummy study on the treatment augmentation strategy for obsessive compulsive disorder patients non-respondent to first line pharmacological treatment. The investigators will compare: fluoxetine maintenance at maximum dosage for additional 12 weeks; the association of fluoxetine with quetiapine; and the association of fluoxetine with clomipramine.
Trial ID Title Status Sponsor Phase Summary

Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Clomipramine Hydrochloride

Condition Name

Condition Name for Clomipramine Hydrochloride
Intervention Trials
Depression 4
Obsessive Compulsive Disorder 4
Premature Ejaculation 4
Obsessive-Compulsive Disorder 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Clomipramine Hydrochloride
Intervention Trials
Disease 8
Compulsive Personality Disorder 6
Compulsive Behavior 6
Obsessive-Compulsive Disorder 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Clomipramine Hydrochloride

Trials by Country

Trials by Country for Clomipramine Hydrochloride
Location Trials
Korea, Republic of 5
Brazil 5
United States 3
Germany 3
Netherlands 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Clomipramine Hydrochloride
Location Trials
Maryland 1
Ohio 1
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Clomipramine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Clomipramine Hydrochloride
Clinical Trial Phase Trials
Phase 4 5
Phase 3 4
Phase 2 4
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Clomipramine Hydrochloride
Clinical Trial Phase Trials
Completed 13
Recruiting 4
Unknown status 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Clomipramine Hydrochloride

Sponsor Name

Sponsor Name for Clomipramine Hydrochloride
Sponsor Trials
Symyoo 4
University of Sao Paulo 2
Fundação de Amparo à Pesquisa do Estado de São Paulo 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Clomipramine Hydrochloride
Sponsor Trials
Other 24
Industry 11
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Baxter
Teva
Express Scripts
Moodys
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.